Ultrasafe safety lancets included in high-cost protection
TLV approves Ultrasafe safety lancets for inclusion in Sweden's high-cost protection scheme from 12 October 2026.
TLV (Swedish HTA) · SwedenTLV approves Ultrasafe safety lancets for inclusion in Sweden's high-cost protection scheme from 12 October 2026.
TLV (Swedish HTA) · SwedenLevetiracetam STADA oral solution 100 mg/ml in 1 ml, 3 ml and 10 ml dosing syringes receives a price increase effective 1 November 2026.
TLV (Swedish HTA) · SwedenTLV approves Soft 28G, 30G and 32G lancets for inclusion in Sweden's high-cost protection scheme from 26 October 2026.
TLV (Swedish HTA) · SwedenTLV approves Chirana Insulin Syringe (five sizes) for inclusion in Sweden's high-cost protection scheme from 12 October 2026.
TLV (Swedish HTA) · SwedenRectogesic (glyceryl trinitrate) rectal ointment receives a higher reimbursement price effective 1 October 2026.
TLV (Swedish HTA) · SwedenTLV approves three Dosivent breathing container products with age-adapted face masks for inhalation therapy to qualify for Swedish high-cost protection from 16 September 2026.
TLV (Swedish HTA) · SwedenAlhemo (concizumab) reimbursement expanded to haemophilia B patients without prior antibody development, effective 1 October 2026.
TLV (Swedish HTA) · SwedenRegister of consumable products withdrawn from Swedish pharmaceutical benefits at manufacturers' request, effective September 2026.
TLV (Swedish HTA) · SwedenMinirin (desmopressin) injection solution receives a higher reimbursement price effective 1 October 2026.
TLV (Swedish HTA) · SwedenTLV approves Zensiv closed one-piece ostomy pouches for inclusion in Swedish high-cost protection scheme from 29 September 2026.
TLV (Swedish HTA) · SwedenTLV approves Zensiv closed one-piece ostomy pouches for inclusion in Swedish high-cost protection scheme from 29 September 2026.
TLV (Swedish HTA) · SwedenTLV approves Flexima Key two-piece soft convex skin barrier plate for inclusion in Swedish high-cost protection scheme.
TLV (Swedish HTA) · SwedenTwo drainable one-piece stoma pouches for infants approved for inclusion in Swedish pharmaceutical benefits from 14 September 2026.
TLV (Swedish HTA) · SwedenTLV approves Ally Powder stoma powder for inclusion in Sweden's high-cost protection scheme from 9 September 2026.
TLV (Swedish HTA) · SwedenLazcluze (lazertinib) for advanced non-small-cell lung cancer is included in Swedish high-cost protection from 1 September 2026.
TLV (Swedish HTA) · SwedenRegister of consumable products withdrawn from Swedish pharmaceutical benefits at manufacturers' request, effective August 2026.
TLV (Swedish HTA) · SwedenList of medicines in various package sizes voluntarily withdrawing from Swedish reimbursement coverage effective 1 November 2026.
TLV (Swedish HTA) · SwedenList of medicines withdrawing from Swedish pharmaceutical benefits on company request, effective 1 October 2026, with alternative reimbursed options available.
TLV (Swedish HTA) · Sweden